Perspective Therapeutics, Inc.
CATX
$3.90
-$0.03-0.76%
AMEX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -79.43% | -27.93% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -79.43% | -27.93% | |||
| Cost of Revenue | 61.88% | 22.38% | |||
| Gross Profit | -63.34% | -23.27% | |||
| SG&A Expenses | -10.09% | 0.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 42.06% | 15.38% | |||
| Operating Income | -42.97% | -15.90% | |||
| Income Before Tax | -47.42% | -18.05% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -44.36% | -18.05% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -44.36% | -20.87% | |||
| EBIT | -42.97% | -15.90% | |||
| EBITDA | -43.35% | -16.22% | |||
| EPS Basic | -44.29% | -20.77% | |||
| Normalized Basic EPS | -47.32% | -17.98% | |||
| EPS Diluted | -44.29% | -20.77% | |||
| Normalized Diluted EPS | -47.32% | -17.98% | |||
| Average Basic Shares Outstanding | 0.06% | 0.08% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||